Transplantation for amyloidosis

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.

Original languageEnglish (US)
Pages (from-to)136-141
Number of pages6
JournalCurrent Opinion in Oncology
Volume19
Issue number2
DOIs
StatePublished - Mar 2007

Fingerprint

Amyloidosis
Transplantation
Immunoglobulin Light Chains
Drug Therapy
Phase III Clinical Trials
Stem Cell Transplantation
Survival Rate
Survival
Mortality
Therapeutics

Keywords

  • Amyloidosis
  • Multiple myeloma
  • Nephrotic syndrome
  • Restrictive cardiomyopathy
  • Stem cell transplantation

ASJC Scopus subject areas

  • Cancer Research

Cite this

Transplantation for amyloidosis. / Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Hayman, Suzanne R.; Kumar, Shaji K.

In: Current Opinion in Oncology, Vol. 19, No. 2, 03.2007, p. 136-141.

Research output: Contribution to journalArticle

@article{cb163cbc119d42f2a3a29fda9a92372e,
title = "Transplantation for amyloidosis",
abstract = "PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.",
keywords = "Amyloidosis, Multiple myeloma, Nephrotic syndrome, Restrictive cardiomyopathy, Stem cell transplantation",
author = "Morie Gertz and Martha Lacy and Angela Dispenzieri and Hayman, {Suzanne R.} and Kumar, {Shaji K}",
year = "2007",
month = "3",
doi = "10.1097/CCO.0b013e32801494c6",
language = "English (US)",
volume = "19",
pages = "136--141",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Transplantation for amyloidosis

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Kumar, Shaji K

PY - 2007/3

Y1 - 2007/3

N2 - PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.

AB - PURPOSE OF REVIEW: High-dose chemotherapy increasingly is being used for the management of patients with immunoglobulin light-chain amyloidosis. We describe nearly 300 patients who had treatment combining high-dose chemotherapy and stem cell transplantation at Mayo Clinic and review the recent literature. RECENT FINDINGS: We review outcomes, engraftment data, and predictors of early mortality. The survival benefit of transplantation, however, has not been verified in a phase III clinical trial. SUMMARY: Partial response rates and complete response rates are prognosticators of survival for patients with amyloidosis. These rates are much higher for patients who receive high-dose therapy and transplantation.

KW - Amyloidosis

KW - Multiple myeloma

KW - Nephrotic syndrome

KW - Restrictive cardiomyopathy

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=33846828703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846828703&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32801494c6

DO - 10.1097/CCO.0b013e32801494c6

M3 - Article

VL - 19

SP - 136

EP - 141

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -